ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Ligand: Glaxo Receives Priority Review for Eltrombopag's Supplemental NDA

By Victoria Stilwell Ligand Pharmaceuticals Inc. (LGND) said the U.S. Food and Drug Administration granted its partner, GlaxoSmithKline PLC (GSK), priority review of the supplemental new drug application for its eltrombopag drug, which treats thrombocytopenia in patients with chronic hepatitis C virus infection. Eltrombopag, known by the brand name Promacta in the U.S., is currently approved in 89 countries as a treatment for patients with chronic immune thrombocytopenia. Thrombocytopenia is a condition in which a patient's blood has a lower-than-normal number of platelets, allowing mild to serious bleeding to occur inside the body or underneath or from the skin. The drug is used to increase the number of cells that help the blood clot in order to decrease the risk of bleeding. Ligand is a biopharmaceutical company that aims to develop or acquire diverse, royalty-revenue-generating assets and couple them with a lean corporate cost structure. Ligand has also partnerships with companies including Merck & Co. (MRK), Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY). Shares of Ligand closed Tuesday at $17.61 and were inactive in premarket trade. The stock is up 48% so far this year. Write to Victoria Stilwell at Victoria.Stilwell@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Merck (MRK)
DateTimeHeadline
08/23/201603:03:00Deal for Medivation Is the Latest In a Line of Similar Acquisitions...
08/22/201612:52:00Pfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
08/10/201616:58:47Statement of Changes in Beneficial Ownership (4)
08/09/201603:03:00Botox Maker Allergan's Revenue Climbs, but Loss More Than Doubles...
08/08/201617:05:00Results from Merck’s Phase 3 Study Evaluating ZEPATIER™ (elbasvir & g...
08/08/201616:41:16Quarterly Report (10-q)
08/08/201614:56:00Allergan Revenue Increases, Though Loss Widens--Update
08/08/201611:59:00MARKET SNAPSHOT: Stocks Retreat From Records As Health-care Stocks...
08/08/201610:20:00MARKET SNAPSHOT: Stocks Fight To Maintain Record-setting Pace...
08/08/201606:45:00REPEAT/FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Pa...
08/05/201619:30:00FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients wi...
08/05/201617:49:32Statement of Changes in Beneficial Ownership (4)
08/05/201612:58:00Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer...
08/05/201610:36:00Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer...
08/05/201610:15:00Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer...
08/05/201609:39:00Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer...
08/05/201609:20:00Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer...
08/05/201609:12:00Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer...
08/05/201608:00:00Merck Announces U.S. FDA Filing Acceptance of New Drug Application...
08/04/201614:30:37Statement of Changes in Beneficial Ownership (4)

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad